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Abstract
Background: There is a paucity of information regarding glucose-6-phosphate dehydrogenase (G6PD) deficiency in
endemic areas for malaria in Latin America.
Methodology/Principal Findings: This study determined the prevalence of the G6PD deficiency in 200 male non-
consanguineous individuals residing in the Ismail Aziz Community, on the outskirts of Manaus (Brazilian Amazon). Six
individuals (3%) were deficient using the qualitative Brewer’s test. Gel electrophoresis showed that five of these patients
were G6PD A
2. The deficiency was not associated with the ethnic origin (P=0.571). In a multivariate logistic regression
analysis, G6PD deficiency protected against three or more episodes of malaria (P=0.049), independently of the age, and was
associated with a history of jaundice (P=0.020) and need of blood transfusion (P=0.045) during previous treatment for
malarial infection, independently of the age and the previous malarial exposure.
Conclusions/Significance: The frequency of G6PD deficiency was similar to other studies performed in Brazil and the
finding of a predominant G6PD A
2 variant will help the clinical management of patients with drug-induced haemolysis. The
history of jaundice and blood transfusion during previous malarial infection may trigger the screening of patients for G6PD
deficiency. The apparent protection against multiple malarial infections in an area primarily endemic for Plasmodium vivax
needs further investigation.
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Introduction
Malaria remains the most important tropical disease in tropical
and sub-tropical areas of the world [1]. In Brazil, approximately
99.5% of malaria cases occur within the Amazon Region, with
544,615 in 2006. The State of Amazonas reported 181,973 cases,
representing 33.4% of the total. In Manaus, the capital of the state,
51,228 cases were reported in that same year, and 40,679 (79.4%)
of these were caused by Plasmodium vivax [2]. The continued high
incidence of malaria in the municipality of Manaus is related to
environmental and socio-economic factors that include high
temperatures, humidity, vector density, unplanned expansion of
the urban peripheral areas and resistance to antimalarials [3,4].
To obtain the radical cure of vivax malaria, primaquine is
prescribed for all patients [5]. Despite a low fatality rate, P. vivax
infection may lead to severe clinical complications related to the
side effects of the drugs, such as haemolysis induced by primaquine
in individuals genetically deficient for G6PD. The worldwide
distribution of this deficiency is a vital consideration in the
development of new antimalarials that may also have the potential
of causing haemolysis [6].
G6PD is an enzyme present in the cytoplasm of all cells, acting
specifically in the maintenance of the integrity of the erythrocytes,
preventing the oxidation of hemoglobin and other cellular proteins
[7]. G6PD deficiency is X-linked and predisposes to hemolysis and
to a lesser extent to methemoglobinemia in those persons in use of
a substance with oxidative properties [8]. The degree of drug-
induced hemolysis may be determined by the G6PD variants
involved, grouped in five classes, identified according to the
activity of the enzyme by electrophoretic and molecular
characteristics [9,10].
G6PD deficiency occurs most frequently in individuals of
African descent, with a frequency ranging from 3.6 to 28.0%
[11,12]. In Asia the deficiency prevalence ranges from 6.0 to
15.8% [13,14], in India it is 10.5% [15], and in the Middle East
the prevalence varies from 3 to 29% [16,17]. In Brazil, a few
studies have found prevalences between 1.7 and 6.0% with a
predominance of the African variant (A
2), with new mutations
already described only in non-endemic areas for malaria [18–21].
To date, there is no community-based estimate of the frequency of
G6PD deficiency in highly-endemic areas for malaria in Latin
America, such as Manaus, and the major variants predominating
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estimate the prevalence of G6PD in an endemic area for malaria
in Manaus, in the Brazilian Amazon.
Results
Of the 200 analyzed samples, six (3%; CI95% 0.97–5.03%)
were deficient for G6PD according to the first screening using the
phenotypic Brewer’s test. The deficiency was confirmed in all the
samples by electrophoresis in agarose gel. Five samples with G6PD
deficiency showed the type A
2 standard on electrophoresis. One
sample disclosed an indeterminate band in the gel, which did not
permit a valid interpretation of the type of deficiency. All the
patients were afebrile at the time of the thick blood smear
collection, but three samples were positive for Plasmodium sp. (two
for P. vivax and one for P. falciparum), disclosing an infection
prevalence of 1.5% (CI95% 0.49–2.51). In Table 1, it is shown
that G6PD was not associated with the ethnic origin, but was
associated with less than three episodes of malaria throughout
their lives and strongly associated with jaundice and need of blood
transfusion during previous malarial infections. Table 2 shows that
the same results were confirmed after a multivariate analysis
(adjusting for age and previous malarial infections).
Discussion
Since G6PD deficiency is a recessive trait linked to the X
chromosome, studying the population frequency of the disorder
exclusively in men is an optimal approach [6]. Measuring the
deficiency in hospital-based studies may underestimate the true
magnitude of the problem, because patients in a haemolytic crisis
may increase their number of peripheral reticulocytes with normal
G6PD values, thereby leading to a false-negative screening for
G6PD deficiency.
The qualitative Brewer’s test for the reduction of methemoglo-
bin is a simple method that uses low-cost reagents. Although only
yielding qualitative results, it is a good screening test and it has
been widely utilized in various studies of selected populations
[20,22].
The biochemical characterization of the isoenzymes demon-
strated a high frequency of the phenotype A
2 G6PD deficiency.
To a certain extent this confirms findings in other Brazilian studies
with different study designs [22,23]. Since one sample in our study
could not be characterized through the biochemical approach,
molecular studies are needed to confirm new possible variants in
further studies. The common African variant G6PD A
2 is usually
a mild/moderate deficiency (10–15% of normal activity in
hemizygous males). In this case, G6PD activity is greatest in
younger cells, so as the red cell population recovers, G6PD activity
increases and hemolysis is controlled. This is what makes drug-
induced G6PD deficiency-related hemolytic anemia in G6PD A
2
subjects a self-limiting problem in most cases [6]. Therefore, our
study supports conservative management of hemolytic crisis for
patients from Manaus, based on their predominant genotype.
Among the six individuals with the G6PD A
2 variant, five were
non-white (but not black) and one was white. This illustrates the
impact of the racial mixing which occurred in the recent history of
Brazil, especially in the Amazon region. A significant immigration
from various parts of Brazil and abroad took place in the
nineteenth century due to rubber extraction activities and during
the twentieth century because of the creation of a tax-free zone
and a growing industrial base in Manaus. The large number of
immigrants from Portugal and Lebanon in Manaus probably
explains this predominant variant found in the studied population,
since G6PD A
2 is frequently seen in these groups [7,17,18].
Epidemiologic studies have suggested that G6PD deficiency
protects against malaria and severe malaria by P. falciparum [24–
26]. The precise mechanism of protection remains unknown. We
Table 1. Crude odds ratios and respective CI95% in the univariate logistic regression analysis of the association between G6PD
deficiency and ethnic origin, previous malaria exposure and previous clinical complications triggered by malarial infection.
Non-G6PD deficient n/N (%) G6PD deficient n/N (%) Total n/N (%) OR (CI95%) P
Ethnic origin
White 25/194 (12.9) 1/6 (16.7) 26/200 (13.0) - -
Non-white 169/194 (87.1) 5/6 (83.3) 174/200 (87.0) 0.74 (0.08–17.43) 0.571*
Previous malaria exposure
,3 episodes 86/194 (44.3) 5/6 (83.3) 91/200 (45.5) 6.27 (1.10–54.75) 0.041**
$3 episodes 108/194 (55.7) 1/6 (16.7) 109/200 (54.5) - -
Previous clinical complications triggered by malarial infection
Jaundice 48/163 (29.4) 5/6 (83.3) 53/169 (31.3) 11.98 (1.30–78.32) 0.012*
Need of blood transfusion 0/163 (0) 4/6 (66.7) 4/169 (2.3) - ,0.001**
*x
2-test.
**Fisher exact test.
doi:10.1371/journal.pone.0005259.t001
Table 2. Adjusted odds ratios and respective CI95% for the
variables associated with G6PD deficiency in multiple logistic-
regression models.
OR (CI95%) P*
Previous malaria exposure**
,3 episodes 4.25 (1.05–60.82) 0.049
$3 episodes - -
Previous clinical complications triggered by malarial infection
Jaundice 7.70 (1.23–299.11) 0.020
Need of blood transfusion - 0.045
*Modified Wilcoxon test for trend.
**Model 1: adjusted for age.
***Model 2: adjusted for age and previous malarial exposure.
doi:10.1371/journal.pone.0005259.t002
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of malaria in the G6PD deficient men enrolled in this study,
independently of their age, suggesting some degree of protection
confered by the deficiency against P. vivax malaria, which is the
major species in the area of the study. This potential protection
conferred by G6PD deficiency needs further investigation.
The impact of G6PD deficiency in this population affected
mostly by P. vivax infection is reflected in their history of
significantly more jaundice and more blood transfusions. This
information could be useful as a first screening for G6PD deficient
patients, to determine who should have a Brewer’s test performed.
This test is not routinely offered to the general population with a
diagnosis of P. vivax malaria in Brazil even though they will receive
a standard 7-day treatment regimen with primaquine (0.5 mg/kg/
day) for radical cure of the parasite. G6PD deficiency therefore
increases the morbidity of P. vivax infection itself and the side
effects of primaquine. In both cases the costs of treatment and
hospitalization are increased. These additional expenses threaten
financial resources and difficulty achieving a radical cure
complicates the control of P. vivax malaria.
Since only a few studies have been published estimating the
prevalence of G6PD deficiency in malaria endemic areas of Latin
America, this study adds information to the global mapping of the
problem, despite a low external validity, as most of the literature
on this issue. Understanding the burden of G6PD deficiency will
guide local antimalarial treatment policies and enable the proper
design of clinical trials for P. vivax radical cure with new
antimalarials having the potential of hemolysis in this population,
such as tafenoquine [27].
Despite the small number of patients enrolled in this population-
based survey, we detected a 3% prevalence of G6PD deficiency in
an endemic area for malaria in Manaus. Accurate information
about this deficiency and its relation to acute hemolysis with the
use of primaquine in the Brazilian Amazon is scarce. G6PD A
2
was confirmed through electrophoretic isoenzyme detection in 5 of
6 patients after the deficiency was initially detected via screening
with the qualitative Brewer’s test. G6PD A
2 was not associated
with a black ethnicity, probably because of the genetically mixed
population of Manaus. The history of jaundice and blood
transfusions associated with prior malaria infections was associated
with G6PD deficiency and may be used as a simple clinical marker
for this entity.
Materials and Methods
The study was carried out in the municipality of Manaus
(03u089 S/60u009 W), in the Ismail Aziz Community, with an
estimated population of 1,500 inhabitants (750 male), including
natives and immigrants (Figure 1). Census data were used to
estimate the population size. The community was chosen due to a
high annual parasite index in 2006 (234/1,000 persons) [2]. The
sample size was calculated for a population of 750 non-
consaguineous men (in order to avoid the consanguinity bias)
with an expected prevalence of G6PD deficiency of 3%, power of
80% and significance level below 5%. Therefore, 200 non-
consanguineous men between 1 and 65 years-old (children under
one year are physiologically G6PD deficient and over sixty-five,
due to the decrease of enzyme activity during senile) were
Figure 1. Geographic localization of the Ismail Aziz Community in an endemic area for malaria in Manaus, Amazonas State, Brazil.
doi:10.1371/journal.pone.0005259.g001
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houses of the community, except those who were consaguineous
relatives of other selected subjects) and enrolled in a cross-sectional
survey of G6PD deficiency, after informed consent has been
obtained. Ethnic origin, previous malaria infection and previous
clinical complications triggered by malarial infection were
acquired through an individual interview, and all the data were
recorded in a standard questionnaire.
Laboratorial techniques
Ten milliliters of venous blood were collected from each person
using EDTA tubes (BD VacutainerH). A qualitative G6PD
screening test by the methemoglobin reduction method was
performed [28]. In all those initially found to be G6PD deficient,
after the whole blood samples were hemolysed, the material was
submitted to electrophoresis [29] for the confirmation of the
deficiency by isoenzyme analysis. The diagnosis of the malaria was
based in the method of the thick blood smear by Walker and
examinated directly to the optic microscope, according to norms
of the World Health Organization, was carried through in all the
individuals [30].
Statistics
The statistical analyses were performed in Epi InfoH 3.3 2004
(CDC/Atlanta). 95% CIs (CI95%) were estimated for all the
observed frequencies of the study. To assess the extent to which
ethnic origin, previous malaria exposure and previous clinical
complications triggered by malarial infection were associated with
G6PD deficiency, odds ratios (OR) with 95% CIs (CI95%) were
estimated by univariate logistic regression analysis (Table 1,
Table 2). Qualitative data were analyzed with the x
2-test or the
Fisher exact-test when indicated. Adjustment for multiple variables
was performed by adding the covariates in a set of multiple
logistic-regression models. Test for trend was conducted through
the exact test for trend (modified Wilcoxon test for trend). A two-
tailed value of P,0.05 was considered statistically significant.
Ethical clearance
The study was approved by the Ethics Committee Board of the
Tropical Medicine Foundation of Amazonas. Informed written
consent was obtained from all participants.
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